Surgical quality issues in ovarian cancer patients

Румянцев, А. А.; Pokataev, I.; Тюляндина, А. С.; Тюляндин, С. А.

doi:10.18027/2224-5057-2018-8-1-31-37

Zlokač. opuholi

2018

DOI: 10.18027/2224-5057-2018-8-1-31-37

|View full text |Cite

Surgical quality issues in ovarian cancer patients

А. А. Румянцев¹,

I. Pokataev²,

А. С. Тюляндина³

et al.

Abstract: There is a major influence of residual tumor on long term survival in advanced ovarian cancer patients. Tumor can directly involve various organs of abdominal cavity. Complex surgical procedures and multiple resections may be necessary in order to achieve complete debulking. However, its rate remains low and sub-optimal debulking is common. Currently, quality of surgical treatment in ovarian cancer is an emerging medical problem. This article is dedicated to review of various approaches to improve quality of c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2022

Publication Types

Select...

Article2

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Retrospective Analysis of Long-Term Survival Outcomes of Primary Cytoreduction and Neoadjuvant Chemotherapy in Patients With Ovarian Cancer Stage Iiic–iv

et al. 2018

Self Cite

View full text Add to dashboard Cite

The choice of treatment strategy in patients with stage IIIC‑IV ovarian cancer (OC) remains the subject of numerous discussions. The reason for this is the unsatisfactory results of randomized trials and the low frequency of primary complete debulking surgery in these studies. We conducted a retrospective analysis to evaluate the survival outcomes in patients with OC stage IIIC–IV (n=314) who underwent treatment between 1995 and 2017. The median progression free survival for primary surgery was 15.6 months, after interval debulking – 11.5 months (p=0.002, HR 0.61: 95 % CI 0.39–0.81). The primary cytoreduction significantly increased the median of overall survival by 19.6 months: from 38.0 months after interval debulking up to 57.6 months after primary cytoreduction (p=0.04, HR 0.64: 95 % CI 0.41–0.99). An increase in the number of optimal interval debulking does not lead to an improvement in the long-term results of treatment in the group of patients after neoadjuvant chemotherapy. Our analysis over the past 20 years has shown that improvement in treatment outcomes is only observed in the primary cytoreduction group due to an increase in the number of complete optimal cytoreductive surgery.

show abstract

Retrospective Analysis of Long-Term Survival Outcomes of Primary Cytoreduction and Neoadjuvant Chemotherapy in Patients With Ovarian Cancer Stage Iiic–iv

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

Immuno-morphological characteristics of bone marrow in patients with ovarian cancer

et al. 2022

View full text Add to dashboard Cite

Background. Nowadays, one of the promising areas is the study of bone marrow in malignant tumors. It is known that hematogenous metastasis to the bone marrow in cancer is a common event. Identification of bone marrow lesions in ovarian cancer, as well as the study of hematopoiesis, can provide additional information about the features of metastasis of this tumor and will make it possible to assess the prospects for targeted therapy. Aim. To assess the possibility of detecting disseminated tumor cells in the bone marrow in patients with ovarian cancer, to establish the frequency of bone marrow damage and to analyze the relationship with the clinical and morphological parameters of the tumor. Materials and methods. This work includes 42 patients with ovarian cancer who received treatment at the Blokhin National Medical Research Center of Oncology. The study was carried out by morphological and immunological methods. Morphological examination of the bone marrow (counting myelograms, calculating myelogram indices, detection of tumor cells) was performed by two morphologists. Disseminated tumor cells were detected using flow cytometry (FACS Canto II, USA, Kaluza Analysis v2.1 software). Monoclonal antibodies were used: CD45, EPCAM. Results. Disseminated tumor cells in the bone marrow of patients with ovarian cancer were determined based on the expression of the EPCAM antigen and lack of expression of CD45 antigen. Disseminated tumor cells were found in 65.2% (n=15)of bone marrow aspirates. Disseminated tumor cells did not correlate with tumor size, lymph nodes status and stage. The frequency of bone marrow damage was higher at stage III and reached 78.6% (11 out of 14 patients), while it was 33.3% (1 of 3 patients) in stage I. 40.0% of positive cases (2 out of 5 patients) were detected at stage IV. Disseminated tumor cells were found in 78.6% (n=11) of bone marrow aspirates in primary ovarian cancer, while in recurrent ovarian cancer they were found only in 44.4% (n=4). Conclusion. The hematogenous dissemination of ovarian cancer in the bone marrow was established. Bone marrow lesions was noted even in the early stages of the tumor process. The frequency of detection of disseminated tumor cells in the bone marrow of patients with ovarian cancer was 65.2%. More frequent bone marrow damage was noted in primary ovarian cancer. The number of myelocytes was significantly lower in primary ovarian cancer without bone marrow damage. The number of lymphocyte was lower in cases of bone marrow lesions.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Surgical quality issues in ovarian cancer patients

Cited by 2 publications

References 15 publications

Retrospective Analysis of Long-Term Survival Outcomes of Primary Cytoreduction and Neoadjuvant Chemotherapy in Patients With Ovarian Cancer Stage Iiic–iv

Retrospective Analysis of Long-Term Survival Outcomes of Primary Cytoreduction and Neoadjuvant Chemotherapy in Patients With Ovarian Cancer Stage Iiic–iv

Immuno-morphological characteristics of bone marrow in patients with ovarian cancer

Contact Info

Product

Resources

About